We use cookies to ensure you get the best experience on our website. Learn more about our privacy policy.
Attention
This is an external link. Click “OK” to continue.
Meet our Board of Directors
Antibe’s Board of Directors comprises experts in corporate governance, growth financing, financial control, risk management, pharmacology, pharmaceutical development and large pharma transactions. All Directors are investors in the Company. Learn about Antibe’s corporate governance practices.
|
Vice Chairman (retired) Mastercard Incorporated, USA |
MBA Schulich School of Business, York University, Canada Walt is the founder of Mastercard’s Center for Inclusive Growth, and has chaired the Centre for Social Impact at Queen’s University, and Convergence Finance. He has been a board member of Save the Children Canada, Big Brothers Big Sisters of Canada, the Royal Conservatory of Music, and the Sunnybrook Hospital Foundation.
|
“Better medicines for pain promise a better world for billions of people.”
Emeritus Professor, Pharmacology William Harvey Research Institute, Queen Mary University, UK | PhD Pharmacology University of London, UK Rod is a recipient of several awards, including the William Withering Prize of the Royal College of Physicians, the Wellcome Gold Medal of the British Pharmacological Society, and the Lifetime Achievement Award of the International Association of Inflammation Societies. |
“I believe that Antibe has made a landmark advance towards a safer treatment for inflammation.”
|
President, CEO and Chairman Kintara Therapeutics, USA Robert is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations, In his previous role, Robert was CFO of San Diego-based Heron Pharmaceuticals, a NASDAQ-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. His career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO, holding that position for ten years. While at Arena, he was involved with its IPO and financings raising more than $1.5 billion. Robert is a member of two public company boards: ASLAN Pharmaceuticals and Saniona AB. |
BBA St. Bonaventure University, USA Member (2010 – 2020) Small Business Advisory Committee, Financial Accounting Standards Board (FASB). Robert is a founding board member of Day for Change, which has funded charities serving underprivileged and abused children in the San Diego area for 20 years.
|
“It’s a great time to work with Antibe’s impressive team to capture the full potential of a uniquely promising drug pipeline and platform.”
|
Chief Business Officer Knight Therapeutics, Canada |
MBA University of Ottawa, Canada Amal has led due diligence, deal structuring and negotiations for more than 20 transactions, with a combined deal value of $500M.
|
“The treatment of pain continues to pose a great challenge as there is a high unmet need for safe and effective pain therapies.”
Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures. | JD Queen’s University, Canada Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain. |
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
Chief Financial Officer Codex DNA, USA | Master of Health Administration (MHA) Cornell University, USA Jennifer managed biopharmaceutical-focused investment funds for Morgan Stanley Dean Witter Advisors, Amerindo Investment Advisors and latterly at Franklin Templeton, where she co-managed the Franklin Biotechnology Discovery Fund. |
“The severe shortcomings of today’s pain medications constitute one of the world’s most pressing medical needs. Patients deserve better. Antibe’s novel drug platform is a promising way forward – I am delighted to be a part of it.”
|
John is widely recognized as an expert in gastrointestinal inflammation and in the development of innovative anti-inflammatory medicines. In the mid-1990s, he co-founded NicOx and chaired its Scientific Advisory Board. (NicOx was the first company to achieve regulatory approval for drugs using gasotransmitters.) |
PhD Medical Science University of Toronto, Canada John received the Premier’s Summit Award in Innovation in 2009, financially the largest prize awarded to an individual scientist in Canada. He is also the recipient of the 2011 William Harvey Medal from the William Harvey Institute in London, UK. John was awarded the Heymans Foundation Medal in 2013—one of only twelve scientists so honored since the foundation was established nearly 50 years ago.
|
“As research delivers new insights into the deep biology of hydrogen sulfide, we are widening our exploration of its therapeutic potential.”
CEO MaRS Discovery District, Canada | Entrepreneurial Masters Program Massachusetts Institute of Technology, USA Yung was recognized as one of Canada’s “Top 40 under 40” leaders earlier in his career and as chief executive of one of Canada’s “50 Best Managed Private Companies”. |
“Antibe ranks amongst the most promising biotech companies that we work with.”
COMMITTEE MEMBERSHIP:
1. Audit Committee
2. HR and Compensation Committee
3. Corporate Governance Committee